黑料网

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at 黑料网 and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

96 Global Health NOW: CDC in Turmoil; As Cholera Crisis Deepens, Africa Launches Emergency Plan; and Quick! To the Bat 鈥楥uddle Ball鈥�! August 28, 2025 Susan Monarez testifies during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions in Washington, D.C., on June 25. Kayla Bartkowski/Getty CDC in Turmoil
The top public health agency in the U.S. faces an escalating crisis as the CDC鈥檚 newly appointed director was abruptly ousted by the Trump administration yesterday, followed by the resignation of top agency officials in protest, .     The background: Only a month in her position, CDC director Susan Monarez clashed with HHS Secretary Robert F. Kennedy Jr. over refusing to support sweeping changes to U.S. vaccine policies, .  

• Yesterday, the FDA limited COVID-19 vaccines to high-risk groups and removed authorization of one of the vaccines available to children, .  

• After Monarez declined to commit to support the changes, the HHS released a statement announcing Monarez was 鈥渘o longer director.鈥� 

The latest: Monarez has refused to step down, with her lawyers saying she was targeted for refusing to support unscientific vaccine directives, and describing her firing as 鈥渓egally deficient鈥� as she has not resigned nor received a formal termination notice, . 

• The attorneys also warned of 鈥渟ystematic dismantling of public health institutions, the silencing of experts, and the dangerous politicization of science.鈥�  

The fallout: Four senior CDC officials resigned in protest, including the agency's chief medical officer, and leaders who oversaw vaccine safety and public health data. 

• 鈥淚 am not able to serve in this role any longer because of the ongoing weaponizing of public health,鈥� wrote Demetre Daskalakis, former director of the National Center for Immunization and Respiratory Diseases, in a departure email. 

GLOBAL HEALTH VOICES EDITOR'S NOTE Long Weekend for Labor Day    GHN will not be published Monday, September 1, in observance of the U.S. Labor Day holiday. We鈥檒l be back with more news on Tuesday, September 2!  鈥�Dayna  The Latest One-Liners   Kenya is launching a mass vaccination campaign next week to stem a surging clade 1b mpox outbreak, per the Africa CDC; 370 cases and seven deaths have been reported since July 2024, with 157 cases documented in the last six weeks.     Countries in the Americas need to immediately increase surveillance and vaccination efforts against pertussis (whooping cough), PAHO announced on Tuesday; cases leapt to 43,751 in 2024鈥攁 10X increase over 2023鈥攁nd include antibiotic-resistant strains.     Denmark and Greenland have officially apologized for their roles in the forced use of contraception for Greenlandic Indigenous girls and women in the 1960s and 70s; ~4,500 Inuit women and girls received IUDs during that time, with many women saying they were not given details of the procedure and did not give their consent.     Disability-related data serve as an early warning indicator for long COVID-19 risk, especially in areas where post-COVID conditions remain underreported,  that analyzed years lived with disability (YLDs) caused by COVID-19 across 920 locations worldwide in 2020 and 2021.   INFECTIOUS DISEASES As Cholera Crisis Deepens, Africa Launches Emergency Plan     Africa CDC and the WHO have launched a continent-wide cholera emergency preparedness and response plan as outbreaks surge across Sudan and surrounding regions.     The new initiative aims to reduce cholera deaths by 90% and eradicate the disease in 20 countries by 2030 by funding vaccines and mobilizing case management support in the face of current outbreaks, .  

• Fighting cholera is critical to 鈥渂uilding a self-reliant Africa that produces its own vaccines and secures its future,鈥� said Zambia鈥檚 President Hakainde Hichilema.  

Urgent need: The continent has seen an alarming rise in cholera, with 213,586 cases and 4,507 deaths reported among African Union member states in 2025 alone.     Sudan is struggling to contain its worst cholera outbreak in decades, with 96,000+ suspected cases and ~2,400 deaths over the last year鈥攊ncluding ~5,000 cases in conflict-riven Darfur, where people in overcrowded camps around besieged El Fasher are 鈥渉ighly vulnerable鈥� to the disease, .  

• And the disease is now spreading in neighboring Chad, where Sudanese refugees have fled. So far, cholera has killed 63 people there and infected 938, . 

Related: Sudan: 鈥楧evastating tragedy鈥� for children in El Fasher after 500 days of siege 鈥�   GLOBAL HEALTH VOICES FOREIGN AID CUTS The Cost of USAID Liquidation   
As USAID-funded projects and organizations shut down worldwide, they are being forced to rapidly offload millions of dollars鈥� worth of equipment鈥攊ncluding cars, mosquito nets, textbooks, generators, printers, phones, mobile health clinics, and more.     Haste and waste: Aid workers, who say they have had little to no guidance from U.S. leadership about what to do with such supplies, have scrambled to sell, donate, or store equipment.  

• But the scale and pace of the shutdowns mean much equipment is handed off without proper documentation鈥攐r is simply being abandoned.  

• Tons of food, antibiotics, contraceptives, and vaccine doses are expiring and being incinerated.  

The cost: The chaotic shutdown may cost taxpayers $6 billion annually 鈥渇or an undetermined amount of time,鈥� not including the sunk cost of wasted goods.        Related:

Polio could paralyse 200,000 children every year unless UK continues global funding 鈥�

Malawi set to run out of TB drugs in a month after US, UK and others cut aid 鈥� 

The US used to be a haven for research. Now, scientists are packing their bags. 鈥�  

The high cost of donor withdrawal: implications for tuberculosis progress 鈥�   

ALMOST FRIDAY DIVERSION Quick! To the Bat 鈥楥uddle Ball鈥�! 
Spectral bats have 3-foot wingspans and outsized teeth, eat meat, and like to hug.  

If you鈥檙e having trouble putting those characteristics together, it鈥檚 understandable. But the lighter side of the night-loving, winged carnivores has emerged from 502 videos of bat roosts in hollow trees in Costa Rica.

The videos by motion-activated cameras revealed never-before observed behaviors, including the family 鈥渃uddle ball鈥� hug, and how a nursing female鈥檚 mate would bring home dead birds and mice to eat, per Marisa Tietge, a researcher at the Natural History Museum in Berlin. 

They also play with bugs and share batwing hugs when they return home after hunting. 

 So sweet鈥攅specially for mammals otherwise known as great false vampire bats. 

  OPPORTUNITY QUICK HITS States are tracking 鈥榠mpostor nurses,鈥� a growing problem since the pandemic 鈥�     Moderna鈥檚 latest COVID-19 vaccine is both approved and 鈥榤ade in Canada鈥� 鈥�     Blue states that sued kept most CDC grants, while red states feel brunt of Trump clawbacks 鈥�     The CDC quietly scaled back a surveillance program for foodborne illnesses 鈥�     How cats with dementia could help crack the Alzheimer鈥檚 puzzle 鈥�     Estimating the predictability of questionable open-access journals 鈥�     Whatever happened to ... the optimist who thinks games and music can change the world 鈥�   Issue No. 2779
Global Health NOW is an initiative of Johns Hopkins Bloomberg School of Public Health.

Contributors include Brian W. Simpson, MPH, Dayna Kerecman Myers, Annalies Winny, Morgan Coulson, Kate Belz, Melissa Hartman, Jackie Powder, and Rin Swann. Write us: dkerecm1@jhu.edu, like us on and follow us on Instagram and X .

Please send the Global Health NOW free sign-up link to friends and colleagues:

Want to change how you receive these emails? You can or . -->



  Copyright 2025 Johns Hopkins Bloomberg School of Public Health. All Rights Reserved. Views and opinions expressed in Global Health NOW do not necessarily reflect those of the Johns Hopkins Bloomberg School of Public Health or Johns Hopkins University.


Want to change how you receive these emails?
You can or .

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative鈥檚 strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to: